Overview

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC

Status:
Active, not recruiting

Trial end date:
2022-01-30

Target enrollment:

Participant gender:

Summary

A Phase 3, Open-Label, Multi-Center, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Participants With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer. 45 sites will be involved in China, 320 subjects will be enrolled.

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Carboplatin
Cisplatin
Pemetrexed